---
title: "Psyence Labs Discloses Investment in PSYENCE BIOMEDICAL LTD. with 30.05% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288586595.md"
description: "Psyence Labs disclosed a 30.05% stake in PSYENCE BIOMEDICAL LTD. via a share-for-share exchange valued at $5 million, filed on June 3, 2026. Psyence Labs holds sole voting and dispositive power over 1,146,159 shares. The BVI-based company, focused on psychedelic pharmaceutical ingredients, intends to hold the investment for potential future acquisition or disposal but has no immediate plans for corporate changes."
datetime: "2026-06-03T13:36:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288586595.md)
  - [en](https://longbridge.com/en/news/288586595.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288586595.md)
---

# Psyence Labs Discloses Investment in PSYENCE BIOMEDICAL LTD. with 30.05% Stake

Psyence Labs Ltd. disclosed a 30.05% stake in PSYENCE BIOMEDICAL LTD.'s common shares. The stake stems from a share‑for‑share exchange completed on Feb. 25, 2026, and was reported in a Schedule 13D filed on Jun. 03, 2026. The exchange valued Psyence Labs’ contribution at $5 million and gave it sole voting and dispositive power over 1,146,159 shares.

**Investor Intent**

Psyence Labs holds the shares for investment and will keep reviewing the position. It may "acquire additional Common Shares" or "dispose of any or all of the Securities," and could use hedging, while it currently has no specific plans for corporate changes.

**Investor's Background**

Psyence Labs Ltd. is a British Virgin Islands company that cultivates, manufactures, and supplies nature-derived psychedelic active pharmaceutical ingredients, including pharmaceutical-grade ibogaine and psilocybin. The company focuses on regulated research and medical markets for psychedelic compounds. It invests strategically in related ventures to support development and commercialization of these therapies.

Original SEC Filing: PSYENCE BIOMEDICAL LTD. \[ PBM \] - SCHEDULE 13D - Jun. 03, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [PBM.US](https://longbridge.com/en/quote/PBM.US.md)
- [PBMWW.US](https://longbridge.com/en/quote/PBMWW.US.md)

## Related News & Research

- [Patrón thinks its biggest selling point is what's not in its tequila](https://longbridge.com/en/news/295660403.md)
- [JYOTHYLAB: Revenue increased but net profit fell as expenses rose; segment reporting was updated](https://longbridge.com/en/news/295631415.md)
- [14:34 ETContext Labs schließt mehrjährige Vereinbarung mit Trafigura und übernimmt Kinertic zur Förderung des CO2-informierten Rohstoffhandels](https://longbridge.com/en/news/295698355.md)
- [07:55 ET/C O R R E C T I O N -- Context Labs/](https://longbridge.com/en/news/295661030.md)
- [Stefan Dyckerhoff Sells 8,994 Shares of Astera Labs (NASDAQ:ALAB) Stock](https://longbridge.com/en/news/295451755.md)